Adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in human endothelial cells

Summary

Tissue factor (TF) plays a pivotal role in thrombus formation and atherogenesis in acute coronary syndrome. Tissue factor pathway inhibitor (TFPI) is a specific physiological inhibitor of TF/ FVIIa complex that regulates TF-induced coagulation. Adiponectin (Adp) is an adipocyte-specific adipocytokine with anti-atherogenic and anti-diabetic properties. Adp inhibits inflammatory cytokine and adhesion molecules expression, and it can prevent endothelial dysfunction. In this study, we investigated the effects of Adp on tumor necrosis factor-α (TNF-α)-induced expression of TF and TFPI in human umbilical vein endothelial cells (HU-VECs), and the signaling transduction pathways involved. It was found that Adp significantly inhibited both TF protein expression and activity in TNF-α-stimulated HUVECs. In the meanwhile, it increased TFPI protein expression and activity for about two folds. Adp also inhibited TF mRNA expression induced by TNF-α, but had no effect on TFPI mRNA expression. The inhibitory effect of Adp onTNF-α-inducedTF expression was prevented by pretreatment with Rp-cAMPs, a PKA inhibitor. Adp increased intracellular cAMP content and PKA activity levels in a dose-dependent manner. Phosphorylation of IκB-α was decreased by Adp, but phosphorylation of p44/42MAPK, SAPK/ JNK, and p38MAPK were not affected. These results suggested that Adp inhibits TF expression through inhibition of a PKA dependent nuclear factor- κB (NF-κB) signaling pathway. It was also found that adiponectin promoted Akt and AMP-activated protein kinase phosphorylation. The inhibitory effect of Adp on TNF-α-induced TF synthesis was abrogated in part by pretreatment with the PI3kinase inhibitor LY 294002, suggesting that Akt activation might inhibit TF expression induced by TNF-α. The inhibitory effect of Adp is almost completely abrogated by inhibition of both the cAMP/PKA pathway and PI3K/Akt pathway. In conclusion, our data indicated that inhibition of NF-κB through stabilization of IκB-α and activation of Akt phosphorylation may mediate the inhibitory effect of Adp on TF expression; but the enhancement effect of Adp on the TFPI production might occur via translational rather than transcriptional regulation.

Keywords

Adiponectin - endothelial cells - tissue factor - tissue factor pathway inhibitor - Akt - PKA

• References

• 1 The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva Switzerland: World Health Organization; 2002
• 2 Butenas S, Undas A, Matthew T. et al. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost 2008; 99: 142-149.
• 3 Wilcox JN, Smith KM, Schwartz SM. et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
• 4 Kaikita K, Takeya M, Ogawa H. et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-188.
• 5 Nemerson Y. Tissue factor and hemostasis. Blood 1998; 71: 1-8.
• 6 Ragni M, Cirillo P, Pascucci I. et al. A monoclonal antibody against tissue factor shortens tissue-plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996; 93: 1913-1920.
• 7 Kirchhofer D, Tschopp TB, Hadvary P. et al. Endothelial cells stimulated with tumor necrosis factor alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 1994; 93: 2073-2083.
• 8 Schecter AD, Giesen PL, Taby O. et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100: 2276-2285.
• 9 Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-325.
• 10 Golino P. The inhibitors of the tissue factor: factor VII pathway. Thromb Res 2002; V257-265.
• 11 Caplice NM, Mueske CS, Kleppe LS. et al. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-1057.
• 12 Crawley J, Lupu F, Westmuckett AD. et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-1373.
• 13 Okamoto Y, Kihara S, Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
• 14 Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
• 15 Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-2568.
• 16 Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005; 05: 129-134.
• 17 Yamauchi T, Kamon J, Waki H, Imai Y. et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.
• 18 Okamoto Y, Arita Y, Nishida M. et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32: 47-50.
• 19 Shimabukuro M, Higa N, Asahi T. et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin EndocrinolMetab 2003; 88: 3236-3240.
• 20 Tan KC, Xu A, Chow WS. et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765-769.
• 21 Fernandez-Real JM, Castro A. et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 2004; 27: 739-745.
• 22 Kobashi M, Urakaze M, Kishida M. et al. Adiponectin Inhibits Endothelial Synthesis of Interleukin-8. Circ Res 2005; 97: 1245-1252.
• 23 Ouchi N, Kihara S, Arita Y, Maeda K. et al. Novel modulator for endothelial adhesion molecules: adipocytederived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
• 24 Chen H, Montagnani M, Funahashi T, Shimomura I. et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
• 25 Motoshima H, Wu X, Mahadev K. et al. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-271.
• 26 Ouchi N, Kihara S, Arita Y, Nishida M. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
• 27 Tomas E, Tsao TS, Saha AK. et al. Enhanced muscle fat oxidation and glucose transport by ADP globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99: 16309-16313.
• 28 Morange PE, Blankenberg S, Alessi MC. et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 05: 472-474.
• 29 Tremoli E, Camera M, Toschi V. et al. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-283.
• 30 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S-68S.
• 31 Nadirl Y, Brenner B, Gingis-Velitski S. et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. ThrombHaemost 2008; 99: 133-141.
• 32 Annex BH, Denning SM, Channon KM. et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
• 33 Dahm A, van Hylckama Vlieg A, Bendz B. et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392.
• 34 Tobias Pischon, Cynthia Girman J. et al. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc 2004; 291: 1730-1737.
• 35 Jensen NS. Obesity and cardiovascular disease: is body structure a factor?. Curr Opin Lipidol 1997; 08: 200-204.
• 36 Nakamura T, Tokunaga K, Shimomura I. et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994; 107: 239-246.
• 37 Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147: 173-180.
• 38 Arita Y, Kihara S, Ouchi N. et al. Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
• 39 Fumiyuki Otsuka, Seigo Sugiyama, Sunao Kojima. et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 2007; 71: 1703-1709.
• 40 Kazumi T, Kawaguchi A, Sakai K. et al. Young men with high-normal blood pressure have lower serum adi-ponectin, smaller LDL size, and higher elevated heart rate than that with optimal blood pressure. Diabetes Care 2002; 25: 971-976.
• 41 Arita Y, Kihara S, Ouchi N. et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898.
• 42 Maeda N, Shimomura I, Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ ADP. Nature Medicine 2002; 08: 731-737.
• 43 Barath P, Fishbein MC, Cao J. et al. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302.
• 44 van Hinsbergh VW, Kooistra T, van den Berg EA. et al. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473.
• 45 Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 372-377.
• 46 Mechtcheriakova D, Schabhauer G, Lucerna M. et al. Specificity, diversity and convergence in VEGF and TNF-alpha signaling events leading to tisue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15: 230-242.
• 47 Zhao B, Stavchansky SA, Bowden RA. et al. Effect of inter leukin-1βand tumor necrosis factor-αongene expression in human endothelial cells. Am J Physiol Cell Physiol 2003; 284: 1577-1583.
• 48 De Martin R, Hoeth M, Hofer-Warbinek R. et al. The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000; 20: E83-E88.
• 49 Neumann M, Grieshammer T, Chuvpilo S. et al. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J 1995; 14: 1991-2004.
• 50 Xu SQ, Mahadev K, Wu X. et al. Adiponectin protects against angiotensin II or tumor necrosis factor {alpha}-induced endothelial cell monolayer hyperpermeability Role of cAMP/PKA signaling. Arterioscler Thromb Vasc Biol 2008; 28: 899-905.
• 51 Malinin NL, Boldin MP, Kovalenko AV. et al. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540-544.
• 52 Ouchi N, Kihara S, Arita Y. et al. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
• 53 Ouchi N, Kobayashi H, Kihara S. et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279: 1304-1309.
• 54 Nagata D, Mogi M, Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 2003; 278: 31000-31006.
• 55 Downward J. Signal transduction. A target for PI(3) kinase. Nature 1995; 376: 553-554.
• 56 Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol Cell Biol 1999; 19: 4798-4805.
• 57 Sizemore N, Lerner N, Dombrowski N. et al. Distinct roles of the IκB kinase α and β subunits in liberating nuclear factor-κB (NF-κB) from IκB and in phos-phorylating the p65 subunit of NF-κB. J Biol Chem 2002; 277: 3863-3869.
• 58 Madge LA, Pober JS. A Phosphatidylinositol 3-ki-nase/Akt pathway, activated by tumornecrosis factor or interleukin-1, inhibits apoptosis but does not activate NF-κB in human endothelial cells. J Biol Chem 2000; 275: 15458-15465.
• 59 Park YC, Lee CH, Kang HS. et al. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS induced NO production from murine peritoneal macrophages. Biochem Biophys Res Commun 1997; 240: 692-696.
• 60 Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-1250.
• 61 Shen B-Q, Lee DY, Cortopassi KM. et al. Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J Biol Chem 2001; 276: 5281-5286.